Yabao Pharmaceutical Group Co Ltd (600351) — Cash Flow-to-Debt Ratio
Yabao Pharmaceutical Group Co Ltd (600351) has a Cash Flow-to-Debt Ratio of 0.22x as of September 2025, meaning its operating cash flow of CN¥129.49 Million could theoretically repay 0% of its total liabilities (CN¥585.77 Million) in one year. See 600351 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Yabao Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2001–2024)
Historical debt coverage capacity for Yabao Pharmaceutical Group Co Ltd across 24 annual periods. Also explore 600351 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Yabao Pharmaceutical Group Co Ltd (2001–2024)
Year-by-year debt coverage analysis for Yabao Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see 600351 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.73x | CN¥471.69 Million | CN¥649.02 Million | ▲ +25.7% |
| 2023 | 0.58x | CN¥497.55 Million | CN¥860.33 Million | ▲ +41.2% |
| 2022 | 0.41x | CN¥460.46 Million | CN¥1.12 Billion | ▲ +4.2% |
| 2021 | 0.39x | CN¥437.50 Million | CN¥1.11 Billion | ▲ +23.4% |
| 2020 | 0.32x | CN¥380.96 Million | CN¥1.20 Billion | ▲ +19.0% |
| 2019 | 0.27x | CN¥425.17 Million | CN¥1.59 Billion | ▲ +13.8% |
| 2018 | 0.24x | CN¥426.60 Million | CN¥1.81 Billion | ▲ +111.5% |
| 2017 | 0.11x | CN¥161.73 Million | CN¥1.45 Billion | ▲ +5.2% |
| 2016 | 0.11x | CN¥155.95 Million | CN¥1.48 Billion | ▲ +16.0% |
| 2015 | 0.09x | CN¥143.47 Million | CN¥1.57 Billion | ▼ -30.3% |
| 2014 | 0.13x | CN¥178.63 Million | CN¥1.37 Billion | ▲ +247.0% |
| 2013 | 0.04x | CN¥56.80 Million | CN¥1.51 Billion | ▲ +149.5% |
| 2012 | -0.08x | CN¥-96.73 Million | CN¥1.27 Billion | ▼ -308.1% |
| 2011 | 0.04x | CN¥40.73 Million | CN¥1.11 Billion | ▲ +181.9% |
| 2010 | 0.01x | CN¥18.57 Million | CN¥1.43 Billion | ▼ -95.4% |
| 2009 | 0.28x | CN¥368.56 Million | CN¥1.31 Billion | ▲ +130.6% |
| 2008 | 0.12x | CN¥102.90 Million | CN¥843.93 Million | ▼ -19.9% |
| 2007 | 0.15x | CN¥105.69 Million | CN¥694.23 Million | ▲ +787.5% |
| 2006 | 0.02x | CN¥11.59 Million | CN¥675.74 Million | ▼ -49.3% |
| 2005 | 0.03x | CN¥26.40 Million | CN¥780.42 Million | ▼ -74.6% |
| 2004 | 0.13x | CN¥79.73 Million | CN¥599.65 Million | ▲ +579.1% |
| 2003 | -0.03x | CN¥-9.62 Million | CN¥346.67 Million | ▼ -119.4% |
| 2002 | 0.14x | CN¥24.29 Million | CN¥169.57 Million | ▲ +3.0% |
| 2001 | 0.14x | CN¥23.59 Million | CN¥169.58 Million | — |